Pharmaceutical company Catalent Inc. continues to strengthen its executive team with the appointment of Joseph Ferraro, who was named senior vice president, general counsel, chief compliance officer and secretary, the Somerset company announced Feb. 13. 

Ferraro will be responsible for managing the company’s global legal and compliance operations in addition to leading Catalent’s legal leadership team and serving on its executive leadership team. He will report to Executive Vice President and Chief Administrative Officer Steven Fasman. 

“Joe has extensive experience as a chief legal officer at public companies, which will be important as Catalent continues to grow in the highly regulated environments in which it operates,” Fasman said in a statement. 

Ferraro most recently served as chief legal officer and secretary for Innovate Corp., where he managed global legal and compliance operations for a publicly traded, diversified holding company with a portfolio of subsidiaries across life sciences, infrastructure, energy and telecommunications, among other industries. 

His previous employers include Prospect Capital – where he advised a multibillion-dollar business development company and other entities on regulatory and compliance issues – as well as the law firms of Sullivan & Cromwell and Boies, Schiller & Flexner, where he focused on corporate and securities law. 

Ferraro earned a Juris Doctor with honors from The Law School at the University of Chicago, where he was a managing editor of The University of Chicago Law Review, and a bachelor’s degree in public and international affairs from Princeton University. 

In July 2022, Catalent welcomed a new CEO, Alessandro Maselli, and launched a new operating structure. These moves were followed in August 2022 by its $475 million acquisition of Metrics Contract Services, a full-service specialty contract development and manufacturing organization with a facility in Greenville, N.C.   

Catalent’s expertise is in development sciences, delivery technologies and multi-modality manufacturing, the company said. 

Its facilities at more than 50 global sites supply about 80 billion doses of nearly 8,000 products annually, according to the company. With a global workforce of more than 18,000, the company generated nearly $5 billion in revenue in its 2022 fiscal year.